CRVS insider transaction filings
Corvus Pharmaceuticals, Inc. — 22 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-15. Screen CRVS transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-15 | 4 | Moore David Scott — Director | Purchase (P): 21,700 @ $11.53 · Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | van den Broek Richard — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Grais Linda — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Thompson Peter A. — Director, 10% owner | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | CLARK IAN T — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-05-20 | 4 | MILLER RICHARD A MD — President and CEO, Director | Purchase (P): 5,000 @ $12.05 · Purchase (P): 1,932 @ $12.01 | EDGAR |
| 2026-04-27 | 4 | Chan Andrew C. — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-01-30 | 4 | Thompson Peter A. — Director, 10% owner | Option exercise (M): 30,000 @ $15 · Option exercise (M): 15,000 @ $9.70 · Option exercise (M): 15,000 @ $12.50 · Option exercise (M): 15,000 @ $3.61 · Option exercise (M): 15,000 @ $2 · Option exercise (M): 15,000 @ $3.27 · +20 more | EDGAR |
| 2025-12-08 | 4 | Jones William Benton — See Remarks | Grant/award (A): 400,000 (derivative) @ $0 | EDGAR |
| 2025-12-08 | 4 | Arcara Jeffrey — Chief Business Officer | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2025-12-08 | 4 | LEA LEIV — Chief Financial Officer | Grant/award (A): 400,000 (derivative) @ $0 | EDGAR |
| 2025-12-08 | 4 | MILLER RICHARD A MD — President and CEO, Director | Grant/award (A): 1,000,000 (derivative) @ $0 | EDGAR |
| 2025-10-06 | 4 | Moore David Scott — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-07-01 | 4 | Thompson Peter A. — Director, 10% owner | Option exercise/expiry (X): 1,397,684 @ $3.50 · Sale (S): 1,176,332 @ $4.16 · Option exercise/expiry (X): 1,397,684 (derivative) @ $0 | EDGAR |
| 2025-07-01 | 4 | ORBIMED ADVISORS LLC — Director, 10% owner OrbiMed Capital GP V LLC — Director, 10% owner | Option exercise/expiry (X): 1,397,684 @ $3.50 · Sale (S): 1,176,332 @ $4.16 · Option exercise/expiry (X): 1,397,684 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Morrison Scott W — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Grais Linda — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Thompson Peter A. — Director, 10% owner | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | CLARK IAN T — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Jones William Benton — See Remarks | Option exercise (M): 19,357 @ $3.50 · Option exercise (M): 19,357 (derivative) | EDGAR |
| 2025-05-09 | 4 | MILLER RICHARD A MD — President and CEO, Director | Option exercise (M): 559,073 @ $3.50 · Option exercise (M): 559,073 (derivative) | EDGAR |
| 2025-04-09 | 4 | van den Broek Richard — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Corvus Pharmaceuticals, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-22 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-06-12 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-14 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-23 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-03-13 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-23 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-20 | 8-K | 8.01 — Other Events | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CRVS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →